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Abstract
Recently, a locus on chromosome 6q22.33 (rs2180341) was reported to be associated with increased breast cancer risk in
the Ashkenazi Jewish (AJ) population, and this association was also observed in populations of non-AJ European ancestry. In
the present study, we performed a large replication analysis of rs2180341 using data from 31,428 invasive breast cancer
cases and 34,700 controls collected from 25 studies in the Breast Cancer Association Consortium (BCAC). In addition, we
evaluated whether rs2180341 modifies breast cancer risk in 3,361 BRCA1 and 2,020 BRCA2 carriers from 11 centers in the
Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Based on the BCAC data from women of European ancestry,
we found evidence for a weak association with breast cancer risk for rs2180341 (per-allele odds ratio (OR) = 1.03, 95% CI
1.00–1.06, p = 0.023). There was evidence for heterogeneity in the ORs among studies (I2 = 49.3%; p =,0.004). In CIMBA, we
observed an inverse association with the minor allele of rs2180341 and breast cancer risk in BRCA1 mutation carriers (per-
allele OR = 0.89, 95%CI 0.80–1.00, p = 0.048), indicating a potential protective effect of this allele. These data suggest that
that 6q22.33 confers a weak effect on breast cancer risk.
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Introduction
Genome-wide association analyses have recently identified
multiple loci conferring genetic susceptibility to breast cancer
[1,2,3,4]. Due to the low relative risks associated with such loci,
however, very large case-control studies are required to confirm
these and estimate the associated risks reliably [5,6].
Recently, a putative breast cancer susceptibility locus at
chromosome 6q22.33 (tagged by rs2180341) was identified by a
two-stage genome wide-association study (GWAS) based on a
phase 1 analysis of 299 Ashkenazi Jewish (AJ) controls and 249 AJ
kindreds with family history of breast cancer and no known BRCA
mutation, followed by phase 2 analysis of 979 AJ controls and
950 AJ breast cancer cases [7]. The association signal spanned an
approximately 100 kb region with two candidate genes, ECHDC1
and RNF146, mapping to this locus. In a follow-up study, an
association was observed in an independent analysis of 1,953
breast cancer cases and 1,467 controls of non-AJ, predominantly
European ancestry (per-allele OR 1.18, 95% CI 1.04–1.33,
p = 0.0083) with some evidence of a stronger association for
ER+ than ER- tumors [8].
Our objective in the current analysis was to further investigate
the association of the 6q22.33 locus with breast cancer risk. To this
end, we genotyped rs2180341 in 27,950 invasive breast cancer
cases and 32,219 controls from 23 case-control studies of primarily
European ancestry and 2 studies of Asians included in the Breast
Cancer Association Consortium (BCAC). We also evaluated
whether rs2180341 was associated with breast cancer risk in
BRCA1 or BRCA2 mutation carriers, by genotyping 5,381
mutation carriers from 11 studies in the Consortium of Investi-
gators on Modifiers of BRCA1/2 (CIMBA).
Materials and Methods
Ethics Statement
Ethics committee approval was obtained for the collection and
genetic analysis of all samples, and an informed written consent
was obtained from all participants. For detailed description, see
Supporting Information S1.
Breast Cancer Association Consortium (BCAC)
Twenty-five case-control studies (described in Supporting
Information S1) contributed data to these analyses. Data were
available on age at study recruitment and ethnicity. Studies were
conducted in Europe, North America, and Australia, among
women of primarily European descent, and in Southeast Asia. For
one study (MSKCC, see study acronyms in Supporting Informa-
tion S1), we included previously genotyped data from a follow-up
analysis reported recently [8]. These data represent an indepen-
dent group of breast cancer cases and controls of non-AJ
European ancestry not used in the prior two-stage GWAS in AJ
population [7].
In the current dataset, we excluded breast cancer cases with in situ
diagnoses (736 cases). Final analyses included 27,950 invasive breast
cancer cases and 32,219 controls of European ancestry, as well as
2,836 invasive breast cancer cases and 2,149 controls of Asian
ancestry. All studies received approval from their institutional
review committees and participants provided informed consent or
were analyzed under specific coding procedures (ABCS).
Consortium of Modifiers of BRCA1 and BRCA2 (CIMBA)
Eleven studies (described in Supporting Information S1) from
Europe, North America, and Australia contributed samples from
carriers to these analyses. Eligible female carriers were aged 18
years or older and had pathogenic mutations in BRCA1 and/or
BRCA2. Data were available on year of birth, age at study
recruitment, age at cancer diagnosis, age of bilateral prophylactic
mastectomy, BRCA1 and BRCA2 mutation description, and
ethnicity. Final analyses included 2,776 invasive breast cancer
cases and 2,605 unaffected mutation carriers.
Genotyping
For most of the BCAC part of the study, the genotyping of
rs2180341 was performed by TaqMan allelic discrimination assay
using the standard protocol, described previously [8]. For the
genotyping of 3 BCAC centers (see Supporting Information S1)
and all CIMBA studies, the Sequenom platform was used
(Sequenom, San Diego, CA, USA). Briefly, the matrix-assisted
laser desorption/ionization time of flight mass spectrometry
(MALDI-TOF MS) was used to determine allele-specific primer
extension products using Sequenom’s MassARRAY system and
iPLEX technology (Sequenom, San Diego, CA, USA). The design
of oligonucleotides was carried out according to the guidelines of
Sequenom and performed using MassARRAY Assay Design
software (version 3.1). Robust quality control criteria, established
by BCAC/CIMBA, were applied as detailed in previous
consortium studies [9,10,11]. Briefly, the genotyping concordance
was verified with internal duplicates and overall data quality was
ensured using independent genotyping of CEU samples by each
genotyping center. We excluded all samples that failed on two or
more of the SNPs genotyped in a particular BCAC/CIMBA
genotyping round. All studies met the specified criteria for call rate
(.95%), and Hardy-Weinberg Equilibrium (HWE; p$0.001).
Statistical Analyses for BCAC
Study-adjusted, fixed-effects models, weighted for each study by
the within- and between-study variances, were used to estimate
pooled odds ratios (OR) and 95% confidence intervals (CI). The
percent of between-study heterogeneity was estimated using the I2
statistic [12,13]. ORs for rs2180341 were estimated under the log-
additive model (per-allele OR), the recessive model, and the 2
degree of freedom (2 df) model, with the common homozygote as
a reference category. Women of non-European ancestry in studies
of predominantly European ancestry were excluded from the
analysis. Separate estimates for women of Asian ancestry were
performed. Analyses stratified on age and estrogen receptor (ER)
status among cases were also performed; missing data for each
variable were excluded from the respective analyses. The p-values
for interaction with age were calculated by comparing the log
likelihood estimates of models with and without an interaction
term for age and genotype (each coded as an ordinal categorical
variable). The p-value for tumor heterogeneity by ER status was
based on the comparison of ORs for the ER-positive (ER+) and
ER-negative (ER-) tumors.
Statistical Methods for CIMBA
Hazard ratios (HRs) and 95% CIs were estimated using a
weighted Cox regression approach as described in detail elsewhere
[14]. Briefly, to correct for potential bias due to over-sampling of
affected carriers the affected and unaffected mutation carriers were
differentially weighted such that the observed breast cancer
incidences in the mutation carrier dataset agreed with external
breast cancer incidences for BRCA1 and BRCA2 mutation carriers.
We used a robust variance approach to allow for the dependence
among related mutation carriers. We also adjusted for study,
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country, ethnicity, and year of birth. Relative risk estimates were
calculated separately for BRCA1 and BRCA2 mutation carriers.
Mutation carriers were censored at the first breast or ovarian
cancer or bilateral prophylactic mastectomy. Carriers who
developed either cancer were censored at the time of bilateral
prophylactic mastectomy only if it occurred more than a year prior
to the cancer diagnosis (to avoid censoring at bilateral mastecto-
mies related to diagnosis in which rounded ages were used). The
remaining carriers were censored at the age of last observation.
This was defined either by the age at interview or age at follow-up
depending on the information provided by the participating
center. Carriers censored at diagnosis of breast cancer were
considered affected in the analysis. Carriers with a censoring/last
follow-up age older than age 80 were censored at age 80 because
there are no reliable cancer incidence rates for BRCA1/2 mutation
carriers beyond age 80.
All analyses were performed with STATA (Version 10.0).
Results
Description of BCAC Study Population
The mean (6SD) age was 53.1 (613.1) years for invasive cases,
52.7 (611.8) years for controls. A total of 88.9% of invasive cases
and 92.9% of controls were of European-descent. Other women
were of Asian ancestry (9.0% cases and 6.2% controls) or unknown
ancestry (2.1% cases and 0.9% controls, respectively).
Figure 1. Forest plot of SNP rs2180341 per-allele odds ratios (ORs) and 95% confidence intervals (CIs) with the risk of breast cancer
among studies from Breast Cancer Association Consortium (BCAC) breast cancer cases and controls of European ancestry. Studies
are weighted and ranked according to the inverse of the between-study and within study variation of the log odds ratio, which is also represented by
the size of the shaded box around the study-specific point estimate. The solid line indicates the OR = 1 and the dashed lined indicates the summary
OR of all studies. A description of the study acronyms can be found in the Supporting Information S1.
doi:10.1371/journal.pone.0035706.g001
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Among controls of European descent, the minor allele frequency
(MAF) of rs2180341 ranged from 22.6% to 28.7% (mean 24.8%;
Supporting Information S1). The MAF was similar for controls of
Asian descent (24.5%, mean of 2 studies).
Association Between rs2180341 and Risk of Breast Cancer
There was some evidence for an association between the G
allele and breast cancer risk (per-allele OR 1.03, 95% CI 1.00–
1.06, p = 0.023, Table 1). The highest risk was observed for GG
homozygotes (OR = 1.07, 95% CI 1.00–1.15; p = 0.044). Signif-
icant between-study heterogeneity (Figure 1) was observed for the
per-allele ORs for women of European ancestry (I2 = 49.3%;
p = 0.004), which was mainly attributable to the strong inverse
associations for kConFab/AOCS and HMBCS, and a strong
positive association for MSKCC and SBCS. Exclusion of these
studies did not alter the overall magnitude of the relative risk
estimate and there was no longer evidence of between-study
heterogeneity (per-allele OR = 1.03, 95% CI 1.00–1.06, p = 0.034;
between-study heterogeneity: I2 = 0.0%, p = 0.80).
There was an indication of effect modification by age (p for
interaction = 0.044; Table 2); we observed no association in the,40
or 40–49 year age groups, but increased association in the age 50–
59 and .60 year age groups (OR = 1.05, 95% CI 1.00–1.11 and
OR = 1.05, 95% CI 1.00–1.11, respectively). The association in the
age group of 50–59 was stronger under the recessive model of
analysis (OR = 1.21, 95% CI 1.06–1.38, p = 0.006).
Among women of Asian ancestry, we did not observe an
association with overall breast cancer risk and the 6q22.33 locus
(Table 1), but there was significant between-study heterogeneity
(I2 = 89.3%; p = 0.002).
We examined the association of rs2180341 with breast cancer
by ER status, which was available from 19 studies that were
conducted predominantly among women of European ancestry.
There was no significant difference in the per-allele OR for
rs2180341 in the risk of ER+ and ER- disease (p for tumor
heterogeneity = 0.21; Table 3). However, the per-allele OR
estimate for ER+ tumors (OR = 1.04, 95% CI 1.00–1.08) was
greater than that for ER- tumors (OR = 0.99, 95% CI 0.93–1.06).
Description of CIMBA Study Population
We also examined the association with rs2180341 in women with
BRCA1 or BRCA2 mutations based on data from 2,776 invasive
breast cancer cases and 2,605 unaffected carriers. Sixty-two percent
of the carriers had a BRCA1 mutation. On average, BRCA1 affected
carriers were censored at age 41.0 (69.3 SD), BRCA1 unaffected
carriers at age 43.1 (612.7 SD), BRCA2 affected carriers at age 44.3
(613.5 SD), and BRCA2 unaffected carriers at age 45.1
(613.5 SD). All study subjects were of European-descent. Genotype
frequencies were in HWE for all studies. Among unaffected carriers,
the MAF of rs2180341 ranged from 19.2% to 33.3% (see
Supporting Information S1) with a mean of 25.0% (Table 4).
Association Between rs2180341 and Breast Cancer Risk in
BRCA1/2 Carriers
The minor allele was statistically significantly associated with a
lower breast cancer risk for BRCA1 mutation carriers, (per-allele
HR = 0.89, 95% CI 0.80–1.00, p = 0.04, Table 4, Figure 2A). The
per-allele HR estimate for BRCA2 mutation carriers was 1.02,
95% 0.90–1.16, p = 0.75 (Table 4, Figure 2B). There was no
evidence of between-study heterogeneity for the estimates among
BRCA1 (p = 0.15) or BRCA2 (p = 0.19) mutation carriers (see forest
plots in Figure 2). ER status was not available for the affected
mutation carriers at the time of analysis.
Discussion
While several recent studies on different ancestries reported an
association of 6q22.33 with breast cancer risk [15,16], none of the
Table 1. Summary odds ratios1 (ORs) and 95% confidence intervals (CIs), adjusted for age and study, for SNP rs2180341 genotypes
and breast cancer risk, Breast Cancer Association Consortium (BCAC).
Genotype No. of studies No. of cases No. of controls MAF2 Pooled
OR1 (95% CI) p-value
Among Women of
European Ancestry
AA 15,526 18,154 1
AG 10,644 12,142 1.03 (0.99 – 1.06) 0.13
GG 23 1,780 1,923 24.8 1.07 (1.00 – 1.15) 0.044
recessive 1.06 (0.99 – 1.14) 0.082
per allele 1.03 (1.00 – 1.06) 0.023
Among Women of
Asian Ancestry3
AA 1,604 1,228 1
AG 1,041 785 0.99 (0.87 – 1.12) 0.85
GG 2 191 136 24.6 0.99 (0.78 – 1.25) 0.93
recessive 0.99 (0.79 – 1.25) 0.96
per allele 0.99 (0.90 – 1.09) 0.85
1ORs were adjusted for study.
2MAF = minor allele frequency.
3Ten studies contributed samples from women self-described as Asian. Two of these studies were conducted in Asian countries and contributed the majority of Asian
samples.
doi:10.1371/journal.pone.0035706.t001
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prior breast cancer GWAS of European populations have
independently identified the 6q22.33 region, possibly due to
limited power in the first stage design of these studies. Noting that
the true magnitude of the effect for 6q22.33 on overall breast
cancer risk is likely to be small, in this report we sought to provide
a more precise estimate of breast cancer risk associated with the
6q22.33 locus in a study of more than 50,000 breast cancer cases
and controls ascertained through the international BCAC. After
restricting the analysis to women of European ancestry, the overall
estimate showed a weak, per-allele association (OR = 1.03, Table 1,
Figure 1), which is smaller than the first replication analysis in non-
AJ European populations (per-allele OR = 1.19) [8]. Findings from
the BCAC study are also consistent with previous observations that
a higher OR was found for minor allele homozygotes. Notably,
there was significant between-study heterogeneity in the BCAC
data, even when the analysis was limited to women of European
ancestry (p = 0.004, Figure 1). For example, while some centers,
(MSKCC, SBCS, or SEARCH) showed comparable effect size
with original observations from AJ GWAS, other centers (e.g.
kConFab, GESBC, HMBCS) yielded risk estimates in the opposite
direction. Such ‘‘flip-flop’’ associations may be due to chance, but
have also been observed in the setting of other known associations,
and may result from local differences in linkage disequilibrium
structure between selected populations, even within the same
ethnicities [17]. Moreover, for two centers ascertained from the
UK population (SBCS and SEARCH) representing a large portion
of the BCAC data (n = 15,478), the magnitude of the association
was more comparable to prior observations in AJ as well as
European ancestry; a per allele OR = 1.09 (95% CI 1.03–1.15;
p = 0.002) was noted in the combined SBCS and SEARCH study
populations compared to OR = 1.18 (95%CI 1.04–1.35, p = 0.008)
in a U.S. study of non-Ashkenazi Caucasians [8]. We hypothesize
that the heterogeneity between studies may largely be attributed to
local population stratification; for example OR estimates observed
in the UK studies differed from those in the Copenhagen (CGPS)
study. While ancestry-informative panels or principal components
from genome-wide scans will need to be incorporated into the
present meta-analysis to quantify potential population stratifica-
tion, such markers were unavailable for the current study. With
the completion of a large ongoing consortia effort on breast cancer
susceptibility (ICOGs) however, this information will be readily
accessible to test the possible confounding effect of the population
substructure on the observed association.
The chance is also a likely explanation of observed heteroge-
neity because individual estimates based on studies with wider
95% confidence intervals, such as kConFab or GESBC, may be
more susceptible to random error [18]. Excluding ‘‘outlier’’ studies
from the present analysis did not alter the magnitude of the OR
estimates, and the statistical significance of the association was only
marginally weaker, suggesting that the observed association is
robust to random error. When pooled with the original AJ GWAS
data [7], the association was stronger (OR = 1.24, 95% CI 1.13–
1.36, p,0.001); however, for the purpose of independent
validation in this study, these original ‘‘discovery’’ data were
excluded from the current analysis.
Another potential concern related to accurate estimate and
adjustment of between-study heterogeneity is the selection of a
statistical model of meta-analysis. In the current study, we report
the results of fixed-effect analysis as opposed to random effect
model. Because of the assumption of low-penetrant effect
uniformly correlated with the response, in the context of the
current meta-analysis of breast cancer case-control studies, the
effect is likely to be similar among the analyzed centers. In
addition, for the small underpowered centers likely subjected to
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random error, overweighing in random model may negatively
impact the accuracy of pooled risk assessment. Therefore, a fixed
effect model was utilized in the present analysis. A parallel analysis
using the random effect models and the results provided were
closely similar results (OR = 1.02, 95% CI 0.98–1.06), with the
between study heterogeneity of p = 0.005.
We have investigated if other factors also contribute to the
heterogeneity of risk estimates observed in this large combined
study. As illustrated in the Supporting Information S1, based on
the age distribution of cases (median age), we found that the cases
from centers with inverse risk estimates were on average 6–17
years younger than the cases from centers showing a susceptible
effect. Based on this observation it is possible that the age
difference, likely attributable to center ascertainments (e.g.
prevalence of familial versus sporadic cases or clinical versus
population – based ascertainments), may also influence the
6q22.33 breast cancer risk estimates. For example, one of the
outlier studies (kConFab) is predominantly a familial-based
ascertainment, with cases and controls on average ,17 years
younger compared to some other studies. This may suggest that
ascertainment differences may possibly contribute to the observed
heterogeneity, although the recent BCAC studies on other low-
penetrant breast cancer GWAS loci suggest such effects to be
marginal. In the present study, however, the age stratified analysis
revealed the association of 6q22.33 with breast cancer risk (per-
allele ORs = 1.05) in the subsets of breast cancer cases .50 years
of age, as shown in Table 3 (p for interaction = 0.044) with the
strongest effect in the age group of 50–59 under the recessive
model (OR = 1.21, 96% CI 1.06–1.38; p-value = 0.006). This
suggests that the breast cancer risk attributed to 6q22.33 allele may
be slightly modified by age, and hence some source of potential
heterogeneity in the risk estimates may stem from the age
distribution related to ascertainment differences between ‘‘youn-
ger’’ (e.g. kConFab) and ‘‘older’’ (e.g. MSKCC, SEARCH)
studies. While the current study does not provide sufficient power
to allow for age-specific meta-analysis, this interaction can be
thoroughly examined with expansion of larger datasets.
The initial reports of this locus suggested a stronger association
for rs2180341 with ER-positive tumors than ER-negative tumors
[8]. We did not replicate this finding in the current study (Table 3),
although there was weak evidence of an association with risk in
ER-positive tumors (per allele OR = 1.04) and no association for
risk in ER-negative tumors (per allele OR = 0.99). Other histo-
pathological variables may also influence the risk effect of
Table 3. Association between SNP rs2180341 and breast cancer risk by estrogen receptor (ER) status among cases and controls of
European ancestry, Breast Cancer Association Consortium (BCAC).
Genotype
No. of
cases
No. of
controls OR1 (95% CI)
No. of
cases
No. of
controls OR1 (95% CI)
p for tumor
heterogeneity
ER+ ER-
AA 6,584 19,554 1 1,930 19,554 1
AG 4,632 13,067 1.04 (1.00 2 1.09) 1,309 13,067 1.01 (0.93 – 1.10)
GG 740 2,079 1.07 (0.97 2 1.18) 186 2,079 0.94 (0.79 2 1.12)
recessive 1.05 (0.96 2 1.16) 0.93 (0.79 2 1.11)
per allele 1.04 (1.00 2 1.08) 0.99 (0.93 2 1.06) 0.21
doi:10.1371/journal.pone.0035706.t003
Table 4. Adjusted1, weighted hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between SNP rs2180341
genotype and breast cancer risk, in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).2
Genotype
No. of
Studies N affected N unaffected MAF3 HR (95% CI) p-value
Among BRCA1 Mutation Carriers
AA 1,041 934 1
AG 582 602 0.87 (0.76 – 1.00) 0.05
GG 11 96 106 24.8 0.85 (0.64 – 1.11) 0.23
recessive 0.89 (0.68 – 1.16) 0.4
per allele 0.89 (0.80 – 1.00) 0.048
Among BRCA2 Mutation Carriers
AA 605 528 1
AG 384 384 0.97 (0.82 – 1.15) 0.73
GG 11 68 51 25.2 1.15 (0.84 – 1.56) 0.38
recessive 1.14 (0.86 – 1.56) 0.33
per allele 1.02 (0.90 – 1.16) 0.75
1Adjusted for birth year and study.
2Restricted to women of European descent.
3MAF = Minor allele frequency.
doi:10.1371/journal.pone.0035706.t004
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rs2180341, and contribute to the observed heterogeneity. While
such scenario is possible, recent studies in BCAC have shown that
besides ER/PR status, the interaction of low-penetarnt alleles from
GWAS with other tumor characteristics is weaker [19], thus it is
unlikely these would substantially impact the observed heteroge-
neity. With the small effect of rs2180341 and the current size of
the present study it was not possible to test the potential interaction
of other tumor clinico-pathological factors. Moreover, for many of
the sub-studies used in the current meta-analysis, this information
was not available, and hence the reduction of power of such partial
analysis may impact the pooled association estimates.
Lastly, our study provides the first estimate of the potential
breast cancer modifying effect of 6q22.33 in carriers of BRCA1
mutations. In the 3,361 BRCA1 mutation carriers in CIMBA, we
observed a statistically significant inverse association with breast
cancer risk (per-allele HR = 0.89, 95% CI 0.80–1.00, p = 0.048,
Table 4, Figure 2A). While this finding may be due to random
effects, we note that OR estimates less than one were observed in
eight of the ten studies. The two remaining studies from this
analysis (PISA and EMBRACE) demonstrated HR greater than
one. Fluctuations in the study-specific risk estimate may be due to
differences in ascertainment bias (e.g., oversampling of familial
cases, selection of younger versus older cases or local population
differences) between studies. As the majority of BRCA1 cancers are
ER-, there is also recent evidence suggesting that E3 ubiquitin-
ligases (related family of RNF146, a candidate gene in 6q22.33)
and BRCA1 may act in conjunction to regulate ER-mediated
pathways in breast cancer tumorigenesis [20,21]. Most interest-
ingly, several recent studies discovered RNF146 to be a critical
player in Wnt signaling pathway, providing an evidence for novel
biochemical properties of the enzyme in ubiquitination of axin, a
critical protein involved in stabilization of beta-catenin [22,23,24].
Besides breast tumorigeneis, this significant observation may
suggest a broader role of RNF146 in other types of common
cancer.
Hence, further functional analysis is needed to link rs2180341
with tumorigenesis. In our original discovery study, we have
demonstrated that rs2180341 tags relatively conserved region of
,100 kb [7]. In the subsequent study [8], our preliminary data
indicated a trend of increased expression of RNF146 with the
dosage of high-risk allele of rs2180341. While sequencing of the
subset of breast tumors did not identify any coding SNPs in
RNF146 associated with the risk allele [8], it is likely that there are
other non-coding variants correlated with rs2180341 that may
explain observed genotype/expression trend. Using the data from
recent release of 1000 genomes we have identified several SNPs
highly correlated with rs2180341; 2 of them with significantly
predictive functional impact on putative transcription binding sites
(Supporting Information S1). Interestingly, rs2180341 maps in a
histone mark region, identified by CHIP-seq (Supporting Infor-
mation S1), suggesting potential involvement of these variants in
regulation of the expression of nearby genes, including RNF146. In
order to provide further biological insight, the more systematic
analysis would be needed to test the correlation of RNF146
expression with identified genetic variants in larger subset of breast
tumors.
In conclusion, this large study found evidence for a weak overall
association between the 6q22.33 locus and sporadic breast cancer
risk. Relative risk estimates for rs2180341 were lower in non-AJ
Europeans as compared to AJ populations. The study illustrates
the difficulties inherent in the reliable estimation of low risk
susceptibility alleles – even with a study as large as the current one,
in which the overall effect was only marginally significant. It is
likely there are many such variants, conferring ORs,1.1, and
characterizing such associations with common diseases disease
presents a major challenge. It is possible that comprehensive
sequencing across the region may identify the true causal variant(s)
with stronger effects. If the heterogeneity among studies is due to
differences in linkage disequilibrium (LD), fine-scale mapping
might also allow identification of more strongly associated variants.
The combined effect of these common variants and other as-yet-
undiscovered rare variants, together with lifestyle risk factors,
could provide the basis for risk algorithms for the preventive
management of breast cancer.
Figure 2. SNP rs2180341 per-allele hazard ratios (HRs) and 95% confidence intervals (CIs) among Consortium of Investigators of
Modifiers of BRCA1/2 (CIMBA) in A. BRCA1 mutation carriers B. BRCA2 mutation carriers. Studies are weighted and ranked according to the
inverse of the between-study and within study variation of the log odds ratio, which is also represented by the size of the shaded box around the
study-specific point estimate. The solid line indicates the OR = 1 and the dashed lined indicates the summary OR of all studies. A description of the
study acronyms can be found in Supporting Information S1.
doi:10.1371/journal.pone.0035706.g002
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Supporting Information
Funding S1 The description of sources of funding for
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Supporting Information S1 Table A: Summary of the 25
breast cancer case studies used in the BCAC analyses
Table B: Genotype frequency among Caucasian BCAC
case and controls, minor allele frequencies (MAF), and
Hardy-Weinberg Equilibrium (HWE) by study Table C:
Summary of the 11 breast cancer case studies used in
the CIMBA analyses Table D: Genotype frequency
among CIMBA case and controls, minor allele frequen-
cies (MAF), and Hardy-Weinberg Equilibrium (HWE) by
study Table E: Ethics committee approvals (IRB ap-
provals) Table F: SNPs from 6q22.33 with the highest
functional impact and highly correlated with rs2180341.
Correlated proxies of rs2180341 (r2>0.8) were extracted
from latest release of 1000 genomes project on ~300
individuals of European ancestry. The functional impact
of all correlated SNPs was assessed using the pipelines
of ANNOVAR suite. The functional impact (FI) of each
SNP for each of 3 selected categories is defined by FI
score. TF binding site prediction also includes DNAI
hypersensitivity data. Conserved elements were assess-
ed using placental 46way analysis. r-square values are
relative to rs2180341.
(DOC)
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AKG HN TH ZF NL KLN SMD NL PK MSA BM AVW FBLH MV
MAR CS RAO MJL MGEMA CMA HJPG JTW EBGG SP MC CTO
DF CL GP RD CC DE K-RO JC FD SH DGE RE PDPP KO GC-T
DFE BGN Y-DK. Analyzed the data: TK MMG. Contributed reagents/
materials/analysis tools: KO ACA PDPP GC-T DFE SEB TD HF FJC
AC BB AM MWRR HB AB LJVV JP NR CYS DK MCS JLH DL ILA
PD AL JB GGG ABS AM JCC BAA MAC AKG HN KLN SMD AVW
MAR SH DGE RE. Wrote the paper: TK MMG KO. Collected samples
and genotype data for the study, and provided critical review of the
manuscript: TK MKH ACA LM AMD SEB BGN HF DK K-YY D-YN
S-HA TD NB NA JIR FJC JO CV XW AC IB GE MWRR BB AM PS
JHK PH HB UH Y-DK AB MKS LJVV LMB NR OF LG JP CT SS AR
NR P-EW J-CY C-NH C-YS MCS JLH FH TVD A-SD SH DL ILA DP
MB EK CJVA RAEM MJH PD SM AL RLM JIA MPZ JB GS LB GGG
ABS JB XC HH SH S-WG JC-C AM V-MK JK VK BAA MAC AKG
HN TH ZF NL KLN SMD NL PK MSA BM AVW FBLH MV MAR CS
RAO MJL MGEMA CMA HJPG JTW EBGG SP MC CTO DF CL GP
RD CC DE K-RO JC FD SH DGE RE PDPP KO GC-T DFE.
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